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Herbal therapies are being used increasingly for the treatment of allergic rhinitis. The aim of this study
was to investigate the possible pharmacological actions and cellular targets of a Chinese herbal formula
(RCM-101), which was previously shown to be effective in reducing seasonal allergic rhinitis symptoms
in a randomized, placebo-controlled clinical trial. Rat and guinea pig isolated tissues (trachea and aorta)
were used to study the effects of RCM-101 on responses to various mediators. Production of leukotriene
B4 in porcine neutrophils and of prostaglandin E2 and nitric oxide (NO) in Raw 264.7 cells were also
measured. In rat and guinea pig tracheal preparations, RCM-101 inhibited contractile responses to
compound 48/80 but not those to histamine (guinea pig preparations) or serotonin (rat preparations).
Contractile responses of guinea pig tracheal preparations to carbachol and leukotriene C4, and relaxant
responses to substance P and prostaglandin E2 were not affected by RCM-101. In rat aortic preparations,
precontracted with phenylephrine, endothelium-dependent relaxant responses to acetylcholine and
endothelium-independent relaxant responses to sodium nitroprusside were not affected by RCM-101.
However, RCM-101 inhibited relaxations to l-arginine in endothelium-denuded rat aortic preparations,
which had been pre-incubated with lipopolysaccharide. RCM-101 did not affect leukotriene
B4 formation in isolated porcine neutrophils, induced by the calcium ionophore A23187; however, it
inhibited prostaglandin E2 and NO production in lipopolysaccharide-stimulated murine macrophages
(Raw 264.7 cells).The findings indicate that RCM-101 may have multiple inhibitory actions on the
release and/or synthesis of inflammatory mediators involved in allergic rhinitis.
Keywords: allergic rhinitis – Chinese herbal medicine – histamine – inducible nitric oxide synthase –
inflammation – leukotriene B4 – prostaglandin E2 – seasonal allergic rhinitis formula (RCM-101)
Introduction
Seasonal allergic rhinitis (SAR), also known as hay fever or
pollinosis, is a common allergic condition worldwide (1–3).
SAR is an immune response to a wide variety of pollens from
grasses, weeds and trees (4). It involves the interaction of the
allergens with specific IgE antibodies bound to high-affinity
Fce receptors on the surface of mast cells and basophils in the
nasal mucosa (5). This induces degranulation of these cells,
resulting in the release of a number of mediators, which are
responsible for a cascade of symptoms. The early symptoms of
SAR, such as sneezing and rhinorrhea, are due to the rapid
release of particular mediators, histamine being considered the
most significant (6). Other mediators, such as prostaglandins,
leukotrienes and nitric oxide (NO) are generally associated
with the late phase responses, which predominantly cause
nasal obstruction (7).
SAR is usually treated symptomatically with histamine H1
receptor antagonists, sympathomimetic vasoconstrictors and
corticosteroids. However, these agents are associated with
certain undesirable side effects and, frequently, do not provide
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complete symptom relief (8–10). Because of the shortcomings
of conventional therapies, alternatives have been sought.
Certain traditional Chinese herbal formulae have long been
used for treating SAR in China and other Asian countries/
regions (11,12), although generally their effectiveness has not
been critically evaluated. Recently, we conducted a rando-
mized, placebo-controlled clinical trial of a traditional Chinese
herbal formula for the treatment of SAR. We demonstrated
that the formula, which will be referred to as RCM-101, was
effective in reducing SAR symptoms (13). The present study
was undertaken to identify possible cellular targets and
pharmacological actions that may be involved in the beneficial
effects of RCM-101 in SAR.
Methods
RCM-101
RCM-101 contains 18 herbal ingredients, selected by the
principles of Chinese medicine theory. Each herb was supplied
in a granulated form by the Min Tong Pharmaceutical Com-
pany, Taichong, Taiwan. The company holds Good Manufac-
turing Practice (GMP) certification from the Australian
Therapeutic Goods Administration (TGA). Each authenti-
cated, quality certified raw herb was tested for heavy metals
and washed and dried. The dried material was extracted in
boiling water for 1–1.5 h and the aqueous extract separated by
filtration (100 mesh). The extract was heated (50–60C) under
reduced pressure (50–70 mm Hg) to reduce the water content
to 60% (2–5 h). The concentrated extract of each herb was
individually combined with an excipient (starch) and the
product dried and ground into fine granules. For each
preparation, 1 g of granulated product was equivalent to 5 g
of the raw herb. The granulated herbal preparations were
supplied, sterilized, in sealed plastic bottles.
The granulated individual herbal ingredients were combined
in the proportions given in Table 1 and encapsulated (500 mg
per capsule, New Product Development Pty Ltd, Queensland,
Australia). The capsules provided a convenient dose-form for
our clinical trial of the formula for SAR (14), such that the
dosage of each individual herb was within the range
recommended by the Chinese Pharmacopeia (14). For the
current study, granules of the herbal formula were taken from
the capsules and extracted as described below. All of the herbal
ingredients of RCM-101 are listed as active raw herbs for
medicines in the Australian Register of Therapeutic Goods.
Reagents
5-Hydroxytryptamine (serotonin), histamine sulfate, phenyl-
ephrine hydrochloride, acetylcholine chloride, compound
48/80, sodium nitroprusside (SNP), prostaglandin E2, leuko-
triene C4, substance P, carbamyl-choline-chloride (carbachol),
NG-nitro-l-arginine methyl ester (l-NAME), l-arginine,
lipolysaccharide Escherichia coli, human recombinant
interferon-g , methysergide maleate, mepyramine maleate,
calcium ionophore A23187, Hanks’ balanced salt solution,
RPMI 1640 medium, fetal bovine serum (FBS), gentamycin
and nordihydroguaiaretic acid (NDGA) were obtained from
the Sigma Chemical Company (St Louis, MO, USA). The
immune-enzyme analysis (IEA) kit, arachidonic acid, prosta-
glandin B2 (PGB2), leukotriene B4 (LTB4), 6-trans LTB4, 6-
trans-12 epi LTB4, 5-hydroxyeicosatetraenoic acid (5-HETE)
Table 1. Composition of RCM-101 (% of granulated herbs by weight*)
Scientific name Botanical name Chinese name %
Flos Magnoliae Magnolia liliflora (Desr.) Xin Yi 3.81
Frutus Schisandrae Chinensis Schisandra chinensis (Turcz.) Wu Wei Zi 2.25
Frutus Terminaliae Chebulae Terminalia chebula Retz. He Zi 13.87
Frutus Xanthii Sibirici Xanthii sibirici Patr. Ex Widd. Cang Er Zi 7.11
Herba Asari Asarum sieboldii Miq. Xi Xin 3.81
Herba Menthae Haplocalysis Mentha haplocalyx Briq. Bo He 4.68
Herba Schizonepetae Tenuifoliae Schizonepeta tenuifolia Briq. Jing Jie 14.21
Pericappium Citri Reticulatae Citrus reticulata Blanco Chen Pi 9.36
Radix Angelicae Sinensis Angelica sinensis (Oliv.) Diels Dang Gui 4.68
Radix Astragali Membranaceus Astragalus membranaceus (Fisch.) Bge Huang Qi 4.68
Radix Bupleuri Bupleurum chinense D.C Chai Hu 3.81
Radix Codonopsitis pilosulae Codonopsis pilosula (Franch.) Nannf. Dang Shen 2.25
Radix Glycyrrhizae Uralensis Glycyrrhiza uralensis (Fisch.) Gan Cao 4.68
Radix Saposhnikoviae Divaricata Saposhnikovia divaricata (Turcz.) Fang Feng 4.51
Rhizoma Atractylodis Macrocephalae Atractylodes macrocephala Koidz Bai Zhu 4.68
Rhizoma Cimicifugae Cimicifuga foetida L. Sheng Ma 4.68
Rhizoma Ligustici Chuanxiong Ligusticum chuanxiong (Hort.) Chuan Xiong 4.68
Semen Plantaginis Plantago asiatica L. Wild. Che Qian Zi 2.25
*One gram of each granulated herb is equivalent to 5 g of the dry weight of the raw herb.
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and 15-hydroxyeicosatetraenoic acid (15-HETE) were
obtained from the Cayman Chemical Company (Ann Arbor,
MI, USA). HPLC-grade methanol was supplied by Selby-
Biolab (Clayton, Victoria, Australia). All other reagents were
of analytical quality and obtained from Merck Pty Ltd (Kilsyth
Victoria, Australia).
The composition of the physiological salt solution (PSS) was
(mM) as follows: NaCl, 118; KCl, 4.7; NaHCO3, 25; MgSO4,
0.45; KH2PO4, 1.03; and CaCl2, 2.5.
Extraction of RCM-101
The granulated combined herbal formula was extracted
with distilled water (123 mg ml1) at room temperature
with continuous agitation for 4 h. The aqueous extract was
collected by centrifugation (5000 r.p.m. for 10 min) and
vacuum filtration. The extract was freeze-dried and the
resultant powder redissolved in water in a concentration of
10 mg ml1. Each 1000 mg of granulated herbal formula
yielded a mean of 17.4 ± 2.6 mg of freeze-dried powder. This
solution was stored at 20C, being diluted to the desired
concentrations on the day of use.
Functional Studies
All experimental procedures involving animals were approved
by RMIT University Animal Ethics Committee and were
conducted in conformity with the Australian National Health
and Medical Research Council guidelines.
Rats (Sprague-Dawley, 200–300 g) and guinea pigs
(Dunkin–Harley, 300–450 g) of both sexes were used. The
animals were killed by asphyxiation with 95% CO2 and then
decapitated. Aortae and tracheae from rats and tracheae from
guinea pigs were removed and set-up in organ baths as
described previously (15). In brief, each aorta and trachea was
cut into four cylindrical lengths (5 mm) and each ‘ring’ was
mounted, vertically, in an 8 ml organ bath containing PSS
bubbled with 95% O2 and 5% CO2. The preparations were
maintained at 37C under a resting tension of 2 g wt (aortic
rings) or 1 g wt (tracheal rings) and were allowed to equilibrate
for 60 min before commencing experimental procedures.
Guinea Pig Tracheal Preparations
The concentration of RCM-101 extract (freeze-dried powder)
used in all experiments with guinea pig tracheal preparations
was 0.4 mg ml1. The effects of RCM-101 on contractile
responses to histamine, leukotriene C4 (LTC4) and compound
48/80 were investigated separately in tracheal preparations.
The effects of the herbal formula on relaxant responses to
substance P and prostaglandin E2 (PGE2) were investigated in
tracheal preparations that had been precontracted with
carbachol (10 mM), again only one agonist being used in
each preparation. With LTC4 and PGE2, a submaximal
response was elicited in the absence and then in the presence
of RCM-101 (LTC4, 30 nM; PGE2, 1 mM). For histamine
(0.1–100 mM) and substance P (0.1–10 mM), concentration
response relationships were established, first in the absence
and then in the presence of RCM-101.
To study the effects of RCM-101 on contractions of guinea
pig trachea induced by compound 48/80, in each tracheal
preparation, a near maximal response to histamine (30 mM)
was first established and then the preparation was challenged
once with compound 48/80 (0.125 mg ml1) (16) in the
presence of either RCM-101 extract, vehicle or the H1-
histamine antagonist, mepyramine (100 mM). In each case
the contractile response to compound 48/80 was expressed as a
percentage of the maximal histamine response.
Rat Tracheal Preparations
To investigate the effect of RCM-101 on contractile responses
of rat tracheal preparations to serotonin, responses to serotonin
(10 mM) were obtained first in the absence and then in the
presence of RCM-101 extract. To study the effects of the herbal
formula on contractions induced by compound 48/80, in each
tracheal preparation, a near maximal response to 10 mMserotonin
was established and then the preparation was challenged once
with compound 48/80 (0.125 mg ml1) (16), in the presence
of either RCM-101 extract, vehicle or the serotonin antagonist
methysergide (100 mM). In each case, the contractile response to
compound 48/80 was expressed as a percentage of the response to
serotonin. As with guinea pig tracheal preparations, the concen-
tration of RCM-101 extract used in all experiments with rat
tracheal preparations was 0.4 mg ml1.
Rat Aortic Preparations
To investigate the effect of RCM-101 on endothelium-
dependent relaxations, cumulative concentration–response rela-
tionships to the relaxant actions of acetylcholine (0.03–10 mM)
were established in phenylephrine (1 mM)-contracted aortic
rings in the absence and then presence of RCM-101 extract
(0.04, 0.1 or 0.4 mg ml1) or vehicle. RCM-101 or vehicle was
introduced into the PSS 15 min before re-establishing the
concentration–response relationship.
To investigate the effect of RCM-101 on endothelium-
independent relaxations, the vascular endothelium was
removed by gently rubbing the vessel lumen with a pair of
forceps (17). The preparations were then set-up in organ baths
as described above, and contracted with 1 mM phenylephrine.
Successful endothelium removal was confirmed by the failure
of acetylcholine (10 mM) to produce relaxation. Cumulative
concentration–response relationships to the relaxant actions of
SNP (0.001–1 mM) were established in the absence and then
presence of RCM-101 extract (0.04, 0.1 or 0.4 mg ml1) or
vehicle (15 min incubation).
In some preparations, the effect of RCM-101 on inducible
nitric oxide synthase (iNOS)-dependent relaxations was
investigated as described previously (18). Briefly,
endothelium-denuded preparations, as described above, were
incubated with lipopolysaccharide (LPS, 100 mg ml1) for 6 h,
and then responses to l-arginine (10, 30 and 100 mM, added
cumulatively) were established in phenylephrine (1 mM)
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contracted preparations, in the absence or presence of RCM-
101 extract (0.1, 0.4 mg ml1) or vehicle. In these experiments
RCM-101 was present throughout the incubation with LPS and
l-arginine challenges, being introduced into the bathing
solution 15 min before contracting the preparations with
phenylephrine (except where indicated otherwise).
Cell Culture Studies
Leukotriene B4 Production
Synthesis of leukotriene B4 (LTB4) was induced in neutrophils
as described previously (19). Porcine blood was collected from
a local abattoir. Neutrophils were isolated using a Percoll
gradient and suspended in Hanks’ buffer, containing 5 mM
HEPES. Suspended neutrophils (2.8 · 106 cells per ml) were
incubated (37C) with arachidonic acid (2.5 mM) together with
RCM-101 extract, NDGA or vehicle, for 5 min. Formation of
LTB4 was then initiated by adding the calcium ionophore
A23187 (2.5 mM) and, 5 min later, the reaction was terminated
by adjusting the pH to 3 with citric acid. Prostaglandin B2
(PGB2, 45 ng) and 15-HETE (83 ng) were then added as internal
standards. The reaction mixture was extracted with 5 ml of
chloroform/methanol (7:3, v/v) and dried under vacuum. The
residue was dissolved in 120 ml of the HPLC mobile phase
(methanol/water/acetic acid, 76/34/0.08, v/v/v, pH 3.0) and
leukotriene metabolites were separated using a Waters HPLC
system equipped with an auto sampler, a multisolvent delivery
system and a Waters 996 Photodiode Array Detector. Standard
curves were prepared for LTB4 (10–200 ng) and 5-HETE (500–
800 ng) (in neutrophil suspensions).
Prostaglandin E2 Production
Murine macrophages (Raw 264.7 cells; American Type
Culture Collection, Rockville, MD, USA) were grown in
RPMI 1640 medium, supplemented with 10% heat-inactivated
FBS, 100 mg ml1 gentamycin, 1.5 g l1 sodium bicarbonate
and 10 mM HEPES, at 37C, in an atmosphere containing 5%
CO2. Cells were subcultured once a week by harvesting them
with trypsin/EDTA and seeding them in 75 cm2 flasks. Once
confluent, the cells were seeded in 24-well plates (1 · 105 cells
per well), in serum-free RPMI medium and then incubated
with LPS (1 mg ml1) for 24 h, in the absence or presence of
RCM-101 extract (1, 100 or 1000 mg ml1). The supernatant
was collected and PGE2 was detected using an EIA kit. The
assay depends on competition between PGE2 and PGE2–
acetylcholinesterase conjugate (PGE2-tracer) for a limited
amount of monoclonal PGE2 antibody. The assays were
carried out according to the manufacture’s protocol, in
triplicate. PGE2 release was calculated using software supplied
by the kit manufacturer.
NO Production
Raw 264.7 cells were cultured as described above, except that
interferon-g (10 ng ml1) was added to the wells during
incubation with LPS/RCM-101. NO production was measured
from the amount of the stable metabolite of NO, nitrite ion.
Aliquots of 5 ml of cell culture medium were added to 1 ml of
0.03 M potassium iodide solution, acidified to pH with 0.07 M
H2SO4. Nitrite ion was then determined by an electrochemical
method using an amiNO-700 sensor and an inNO system
(Innovative Instruments Inc., USA). The apparatus was
calibrated with acidified nitrite solution, over the range of
50–200 nM, in accordance with the manufacturer’s specifica-
tion. The sensitivity of the sensor was determined to be 123 ±
8.9 pA nM1 (n ¼ 25).
Statistical Analysis
Data are expressed as means ± standard errors of the mean
(SEM). The statistical significance of differences between
means was determined by unpaired, two-tailed Student’s t-test
or, for more than two groups, by first testing for global
differences by one- or two-way analysis of variance (ANOVA)
and then testing for differences between predetermined pairs
of means by Dunnet’s test. Probability levels less than 0.05
(P < 0.05) were taken to indicate significant differences. For
the 5-lipoxygenase assay, the data were analyzed using Water
Millenium Software, Version 3.2, results being expressed as
percentage inhibition, the vehicle control being taken as 0%
inhibition.
Results
Contractile Responses Induced by Compound 48/80
Markedly Reduced in Guinea Pig Trachea
RCM-101 extract (0.4 mg ml1) did not significantly affect
contractile responses to histamine (Fig. 1A). Similarly,
contractile responses to carbachol (0.1–30 mM) and LTC4
(30 ng ml1) were unaltered by RCM-101 in the same
concentration (data not shown). Relaxant responses of tracheal
preparations, precontracted with 10 mM carbachol, to PGE2
(1 mM) and substance P (0.1–10 mM) were also unaltered by
RCM-101 (data not shown). In contrast, as shown in
Fig. 1B, contractile responses induced by compound 48/80
(125 mg ml1) were markedly reduced by RCM-101
(0.4 mg ml1). The histamine H1 antagonist (100 mM)
mepyramine, reduced responses to 48/80 to about the same
extent as RCM-101 (Fig. 1B).
Contractile Responses Induced by Compound 48/80
Markedly Reduced in Rat Trachea
Contractile responses to 10 mM serotonin were not signifi-
cantly affected by 0.4 mg ml1 RCM-101 extract (Fig. 2A).
However, as with guinea pig tracheal preparations, contrac-
tions of rat tracheal preparations induced by compound 48/80
(125 mg ml1) were significantly reduced by 0.4 mg ml1
RCM-101 (Fig. 2B). RCM-101 also slowed the rate of onset of
contraction of rat tracheal preparations to compound 48/80, the
maximum tension developing in 2.6 ± 0.2 min (n ¼ 12) in the
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vehicle-treated group and in 6.2 ± 0.5 min (n ¼ 8) in the
presence of RCM-101. Compound 48/80 responses were also
reduced by 100 mM methysergide (Fig. 2B).
Inhibition of iNOS-Mediated Relaxations of
Endothelium-Denuded Rat Aortic Preparations
to L-Arginine
In LPS-treated endothelium-denuded aortic preparations,
precontracted with phenylephrine (1 mM), l-arginine
(10, 30 and 100 mM) produced concentration-dependent
relaxation. The presence of RCM-101 extract (0.4 mg ml1)
during the 6 h incubation with LPS markedly reduced the
responses to l-arginine (Fig. 3). A lower concentration of
RCM-101 (0.1 mg ml1) introduced for the LPS incu-
bation, produced smaller reductions in l-arginine responses
(Fig. 3). If RCM-101 was only introduced into the tissue
bathing solution 15 min before the first exposure to
l-arginine, the responses to l-arginine were not significantly
different from control responses (Fig. 3). In contrast,
l-NAME (100 mM), introduced 15 min before the first
exposure to l-arginine, markedly reduced the l-arginine
responses (Fig. 3).
The inhibitory effects of RCM-101 (present during
LPS incubation) and of l-NAME (introduced after LPS
incubation) were only partly reversed by repeated exchanges
Figure 1. Guinea pig tracheal preparations. (A) Histamine-induced contractions were unaffected by RCM-101 (0.4 mg ml1). Data are means ± SEM (n¼ number
of preparations). (B) Inhibition of compound 48/80-induced contractions by RCM-101 (0.4 mg ml1) and mepyramine (100 mM). Responses are expressed as
percentages of the response to 30 mM histamine. Data are means ± SEM. *P < 0.05, Student’s unpaired t-test.
Figure 2. Rat tracheal preparations. (A) Contractions to serotonin (10 mM) were unaffected by RCM-101 (0.4 mg ml1). Data are means ± SEM (n ¼ number of
preparations). (B) Inhibition of compound 48/80-induced contractions by RCM-101 (0.4 mg ml1) and methysergide (100 mM). Responses are expressed as
percentages of pre-treatment serotonin response. Data are means ± SEM. *P < 0.05, Student’s unpaired t-test.
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of the tissue bathing solution over a 5 min period (data not
shown).
RCM-101 extract (0.04, 0.1 and 0.4 mg ml1) did not
significantly affect endothelium-dependant relaxations to
acetylcholine (0.03–10 mM) or endothelium-independent
relaxations to SNP (0.001–1 mM) (data not shown).
LPS-Stimulated Prostaglandin E2 Production in Murine
Macrophages Blocked by RCM-101
Unstimulated murine macrophage (Raw 264.7) cells incubated
in serum-free RPMI medium for 24 h had a baseline con-
centration of PGE2 of 52 ± 10 pg ml
1. Incubating the cells
with LPS (1 mg ml1) increased the PGE2 level to 7442.4 ±
766 pg ml1 (n ¼ 6). This was reduced in a concentration-
dependent manner by RCM-101 extract (10, 100 and
1000 mg ml1), when present during incubation with LPS.
Indomethacin, present during LPS incubation, in each of the
concentrations tested (1, 10 and 100 mM), completely blocked
PGE2 production. The data are shown in Fig. 4.
RCM-101 Did Not Affect LTB4 Synthesis in
Porcine Neutrophils
As shown in Fig. 5, LTB4 formation in porcine neutrophils
was not significantly affected by RCM-101 extract in
concentrations of 1, 10 and 100 mg ml1. In contrast, NGDA
(0.1–10 m1, produced concentration-dependent inhibition of
LTB4 production.
Inhibition of LPS/Interferon-g-Induced NO Production
in Murine Macrophages
The concentration of NO in the culture medium of unstimul-
ated murine macrophage (Raw 264.7) cells was 46.31 ±
8.0 nM (n ¼ 6). The concentration in the cell culture medium
after incubation of RAW 264.6 with LPS and interferon-g
was 768.8 ± 125.5 nM. As shown in Fig. 6, RCM-101
extract (10–1000 mg ml1) reduced the NO level in a
concentration-dependent manner.
Discussion
In SAR, mast cell-derived mediators, such as histamine, are
generally considered to be responsible for the acute allergic
symptoms (20). These mediators act on the smooth muscle
cells of small blood vessels, blood platelets, mucous glands
and on sensory nerve endings to produce symptoms such as
nasal congestion, nasal and throat itching, sneezing and
hypersecretion (21).
The present study has demonstrated that a Chinese herbal
formula RCM-101, which is effective in the symptomatic
treatment of SAR (13), inhibits the contractile responses of rat
and guinea pig tracheal preparations to the mast cell activator,
compound 48/80. However, the aqueous extract of RCM-101
did not affect contractile responses of tracheal preparations
elicited by exogenous histamine (guinea pig preparations) or
serotonin (rat preparations), most likely this indicates that
RCM-101 inhibits the release of histamine and serotonin in the
respective tracheal preparations. The involvement of histamine
and serotonin in compound 48/80-induced responses is
evidenced by the findings with specific histamine and
serotonin antagonists (22). It is noted, however, that although
mepyramine and methysergide markedly reduced the effects of
compound 48/80 they did not abolish the responses, indicating
Figure 3. Endothelium-denuded, phenylephrine-contracted rat aortic prepara-
tions in which NO synthase was induced by incubation for 6 h with
lipopolysaccharide (LPS). RCM-101 (0.1 and 0.4 mg ml1), when present
throughout LPS incubation, inhibited responses to l-arginine. The responses
were unaffected by RCM-101 (0.4 mg ml1) when it was introduced 15 min
before the first l-arginine challenge. In contrast, l-NAME (100 mM),
introduced 15 min before the first l-arginine challenge, inhibited the
responses. Data plotted are means ± SEM (n ¼ number of preparations).
*P < 0.05, two-way ANOVA.
Figure 4. Inhibition of PGE2 production in LPS-stimulated Raw 264.7 cells
by RCM-101 and indomethacin. Data plotted are mean (±SEM) percentage
inhibition of control PGE2 production (n¼ 6 in each case). *P< 0.05, one-way
ANOVA and Dunnet’s test.
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that mediators other than histamine or serotonin may also be
involved. Indeed, given that mast cells contain a variety of
inflammatory mediators, in addition to histamine (or seroto-
nin), it is possible that the inhibitory action of RCM-101 on the
responses to compound 48/80 may have been due to the
blockade of the contractile action of an agent or agents other
than histamine (or serotonin).
Previous studies suggest that prostaglandins and leuko-
trienes are likely to be involved in the late phase symptoms of
SAR (8). For example, serotonin induces sneezing and
rhinorrhea without congestion while leukotrienes and prosta-
glandins cause congestion without rhinorrhea (9). Among
different leukotrienes, LTB4 is released during the immediate
phase response by infiltrating neutrophils (23).
PGE2 has been shown to be involved in both the early and
late phases of SAR. In the early phase, PGE2 is released from
mast cells whilst, in the late phase, it is released from
basophils and eosinophils (20,24). In the present study, in
which production of PGE2 by murine macrophages was
initiated by LPS, RCM-101 inhibited PGE2 production. The
exact mechanism involved in the inhibition was not investi-
gated; however, it may involve modification of cyclooxygen-
ase (COX) activity or of expression of the enzyme. There are
two isoforms of COX, and the isoform responsible for the
induced PG production is COX-2. Previous studies have
shown that the herbs Rhizome Cimicifugae and Radix
Glycyrrhizae, which are constituents of RCM-101, have
potent COX2 inhibitory effects (25). In addition, Radix
Glycyrrhizae is known to have anti-inflammatory activity.
Both topical and oral administration glycyrrhetinic acid, a
constituent of Radix Glycyrrhizae, prevent ear edema and to
inhibits PGE2 and LTC4 formation in mice, induced by
arachidonic acid, with approximately the same potency as
NDGA (26).
NO is an important mediator in various inflammatory
processes (27–30). In SAR, the level of NO in the parasinus
is dependent on iNOS (31), and there is evidence that exhaled
NO is elevated in subjects with allergic rhinitis (32,33). It has
been suggested that increased production of NO in the nasal
mucosa may promote vasodilatation and modulate the
responsiveness/activity of sensory nerves, leading to nasal
congestion, rhinorrhea and sneezing (30). The present finding
of inhibition by RCM-101 of l-arginine-induced vasodilata-
tion in LPS-treated aortic rings indicates that RCM-101 may
inhibit iNOS-dependent NO production, since the responses to
exogenous NO were not affected by RCM-101. The finding
that RCM-101 was without effect on responses of rat aortic
preparations when it was introduced after the preparations had
been incubated for a prolonged period with LPS (15 min
before l-arginine), indicates that unlike l-NAME (NOS
inhibitor), it does not interfere with the action of preformed
iNOS. Previous studies in denuded rat aorta have demonstrated
induction of NO synthase by LPS, leading to increased
production of NO (34). The finding that the herbal formula
inhibited LPS/interferon-g-induced NO production by
murine macrophage cells further supports the suggestion
that RCM-101 inhibits iNOS-dependent NO production.
Further studies will be necessary to elucidate the exact
mechanism involved in inhibition of iNOS-mediated NO
production by RCM-101, which may involve modification
of existing enzyme activity or altered expression of iNOS
protein or its gene.
The present findings with RCM-101 are consistent with
previous studies on some of the individual herbal ingredients of
the formula. Naturally occurring furanocoumarins (imperatorin
and deltoin), isolated from Radix Saposhnikoviae, inhibited
iNOS protein expression but not the enzyme itself (35).
Polysaccharides from Angelica sinensis have also been shown
to reduce the levels of endogenous NO and the expression of
iNOS (36). Luteolin, which is present in Herba Schizonepetae
(37), markedly lowers NO production by reducing iNOS
enzyme expression without inhibiting the enzyme activity
(38). Polyacetylenes isolated from Radix Saposhnikoviae were
found to inhibit NO production induced by LPS/interferon-g in
Figure 5. LTB4 formation in porcine neutrophils was unaffected by RCM-101
(1, 10 and 100 mg ml1). Nordihydroguaiaretic acid (NDGA; 0.1, 1 and
10 mg ml1) produced concentration-dependent inhibition of LTB4 formation.
Data plotted are means ± SEM (n ¼ 8 in each case). *P < 0.05, one-way
ANOVA and Dunnet’s test.
Figure 6. Inhibition of LPS/interferon-g-stimulated NO production
(determined as the stable metabolite nitrite) in Raw 264.7 cells by RCM-101.
Data plotted are mean percentage of control NO production (±SEM; n ¼ 6 in
each case). *P < 0.05, one-way ANOVA and Dunnet’s test.
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macrophages (35). In addition, costunolide, found in Magnolia
grandiflora, reduced NO production by downregulating iNOS
mRNA. It also reduced iNOS expression by inhibiting binding
of the transcription factor nuclear factor-kappa B (NF-kB).
Costunolide was also shown to inhibit phosphorylation of
IkB (39), thereby enhancing its inhibitory action on NF-kB.
Radix Glycyrrhizae increases blood cortisone levels (40), which
may, in turn, inhibit iNOS gene transcription by decreasing NF-
kB activity and inducing IkB-a (41). Thus, it is likely that
multiple ingredients of RCM-101 may be involved in its
inhibition of iNOS-dependent NO production. RCM-101 did
not inhibit eNOS-dependent relaxations to acetylcholine or
direct relaxations to the NO donor, SNP. The inhibition of the
iNOS pathway by RCM-101 indicates that it selectively
interferes with inflammatory processes in the late phase of
SAR (26).
In conclusion, the results obtained in this study indicate
that RCM-101 may have multiple pharmacological actions
including inhibition of histamine release from mast cells,
inhibition prostaglandin formation and inhibition of inducible
NO synthase-mediated NO production/response in target
cells. The exact inhibitory mechanisms and which herbal
constituents contribute to these effects require further
investigation.
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